Bruker Corporation (Billerica, MA, USA) will acquire the preclinical imaging business of Oncovision (Valencia, Spain), which will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging.
Oncovision’s medical imaging devices are used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer, while Bruker provides scientific research instruments and analytical solutions in the areas of life science molecular research, applied and pharma applications, microscopy, nano-analysis and industrial applications, as well as cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics.
For the past five years, Bruker and Oncovision have been enjoying an exclusive marketing agreement for Albira PET/SPECT/CT systems, and have jointly developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology, which boasts of the highest full field-of-view PET resolution and sensitivity. Both the companies have also worked together on a high-performance preclinical 3 Tesla SiPM-PET/MRI system.
Dr. Wulf I. Jung, President of Bruker's Preclinical Imaging Division, stated, "With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations."
Dr. Jung added, "This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira Si PET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements."
Ignasi Vivas, CEO of Oncovision, said, "Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists."